Verificar estado da encomenda

Faça parte de uma comunidade de amantes de livros de todo o mundo e tenha acesso a uma série de benefícios. Crie uma conta gratuitamente

Correio DHL 7.99 € Correio DPD 4.49 € Ponto DPD 3.99 € Correio GLS 5.49 € Correio MRW 5.49 € Ponto GLS 4.49 €

Contacto

Como comprar

Ajuda

A minha conta

▸ Vazio :-(

Activity-based proteomics

Name: Activity-based proteomics
Brand: Sudwestdeutscher Verlag Fur Hochschulschriften AG
SKU: 07148241
Price: 50.55 EUR
Availability: InStock
Author: Thomas Wiedl
ISBN: 9783838131375

Thomas Wiedl

Língua

Inglês

Livro Capa mole

Código Libristo: 07148241

Editoras Sudwestdeutscher Verlag Fur Hochschulschriften AG, fevereiro 2012

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ra... Descrição completa

Código Libristo: 07148241

123 b

50.55 €

Armazenamento externo Envio em 8-11 dias

Até 30 dias para devoluções

Os clientes também compraram

Die Schelme von Steinach, Erzahlung fur die Jugend Josephine Siebe

Adobe ePub DRM

2.20 €

Wissensbasierte Regionalentwicklung - Das Konzept der Lernenden Region Felix Hacker

Capa mole

16.98 €

Fosilie Michal Kašpárek

Capa mole

6.02 €

Oscar Wilde's "Dorian Gray" in drei deutschen Übersetzungen Corinna Clauß

Capa mole

49.44 €

Guida Completa per Il Tuo German Hunting Terrier Bonetti Geminiano Bonetti

Capa mole

14.87 €

GLEM PIERRE-YVES

Capa mole

5.42 €

Les Français de l'an 40 Crémieux-Brilhac

Capa mole

16.78 €

Ágnes ve skleněném městě Ivana Peroutková

Livro de capa dura

10.24 €

Apple Of The Sun - The Argument For The Universal Gravitational 'Constant' Not Being Constant ???

Capa mole

12.05 €

Legislacion de marcas, patentes y diseño industrial RICARDO ALONSO

Livro de capa dura

70.75 €

Šumava krásná a tajemná Martin Čihař

Livro de capa dura

16.17 €

Zulassigkeit der Nothwehr gegenuber beleidigenden AEusserungen, Leopold Bauke

Capa mole

12.35 €

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ranges from 80% in early stages to less than 5% in advanced disease. Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung malignancies, 40% of which are adenocarcinomas representing one of the most common lung cancer subtypes. Currently, prognosis is mostly determined based on the extension of disease at diagnosis. Thereby it has become evident that predicted and real outcomes can vary significantly, even for patients with the same stage of disease. Thus, novel biomarkers that refine prognosis with a reliable clinical significance are clearly needed. Therefore we aimed to implement an activity-based proteomics platform representing a powerful tool in the search for novel disease biomarkers.